Item 5.07. Submission of Matters to a Vote of Security Holders.
On February 8, 2023, Dermata Therapeutics, Inc. (the "Company") held a special
meeting of stockholders (the "Special Meeting"). The matters voted on at the
Special Meeting were: (1) the adoption and approval of an amendment to the
Company's Amended and Restated Certificate of Incorporation, as amended (the
"Charter"), to effect a reverse stock split of the issued and outstanding shares
of the Company's common stock, par value $0.0001 per share (the "Common Stock"),
at a specific ratio, ranging from one-for-two (1:2) to one-for-forty (1:40),
with the exact ratio to be determined by the Company's board of directors
without further approval or authorization of the Company's stockholders (the
"Reverse Stock Split Proposal") and (2) the approval of the adjournment of the
Special Meeting to the extent there are insufficient votes at the Special
Meeting to approve the Reverse Stock Split Proposal (the "Adjournment
Proposal").
At the Special Meeting, both of the matters voted on were approved, based upon
an aggregate of 12,321,848 shares of Common Stock outstanding as of December 28,
2022, which was the record date for the Special Meeting. The final voting
results were as follows:
Proposal No. 1: The Reverse Stock Split Proposal was approved by a vote of
stockholders as follows:
Votes For Votes Against Abstentions
7,622,928 135,481 39,669
Proposal No. 2: The Adjournment Proposal was approved by a vote of stockholders
as follows:
Votes For Votes Against Abstentions
7,681,932 87,554 28,592
2
© Edgar Online, source Glimpses